Stock DRMA DERMATA THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Consensus Dermata Therapeutics, Inc.

Equities

DRMA

US2498454055

Delayed Nasdaq
Other stock markets
 01:03:45 2024-05-23 pm EDT 		5-day change 1st Jan Change
3.66 USD +1.10% Intraday chart for Dermata Therapeutics, Inc. -29.62% -60.00%
Mar. 21 Dermata Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Jan. 05 Wall Street Set to Open Lower as Monthly Jobs Data Much Stronger Than Expected MT

Evolution of the average Target Price on Dermata Therapeutics, Inc.

Price target over the last 5 years

History of analyst recommendation changes

0a7e27e91.aIiFO0SxHZvBaqtGUB1KIGKzY1ZN4iiMhApNasHH2fM.Ef28fnzaT9KiK9EUFyUkZhXrNRd-iB3_qW00WY2A4ZYS--tUC8dw1KYy2A~ccc3c8950e596947b3575d0005f70738

Analyst Recommendations on Dermata Therapeutics, Inc.

Maxim Adjusts Price Target on Dermata Therapeutics to $4 From $16, Keeps Buy Rating MT
DERMATA THERAPEUTICS : Brookline Capital Starts Dermata Therapeutics at Buy with $14 Price Target MT
DERMATA THERAPEUTICS : Maxim Starts Dermata Therapeutics at Buy with $9 Price Target MT
More recommendations

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
1
Last Close Price
3.62 USD
Average target price
10 USD
Spread / Average Target
+176.24%
High Price Target
10 USD
Spread / Highest target
+176.24%
Low Price Target
10 USD
Spread / Lowest Target
+176.24%

Consensus detail

Consensus revision (last 18 months)

Analysts covering Dermata Therapeutics, Inc.

Maxim
Brookline Capital Management

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar
  1. Stock Market
  2. Equities
  3. DRMA Stock
  4. Consensus Dermata Therapeutics, Inc.